FDA to review whether to allow more access to certain peptides
The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.
medicalxpress.comHere’s what’s currently known about FDA-approved peptides and recent developments.
-
FDA-approved peptide-related drugs in 2023–2024: The FDA approved several peptide- or peptide-like therapies as part of broader drug categories (peptides and oligonucleotides). A 2023–2024 harvest highlighted multiple pepTIDES and oligonucleoTIDES approvals, indicating growing activity in this space. In particular, the 2023 TIDES harvest noted nine total approvals, including a subset that were peptide-based.[1][5]
-
2024 regulatory movements affecting peptides: In 2024, the FDA approved at least a couple of peptide-related products (notably including oligonucleotides) as part of the year’s total drug approvals, underscoring continued progress in peptide- and oligonucleotide therapeutics. Additionally, there have been regulatory discussions and advisory activity around peptide safety and compounding access, signaling ongoing evolution in how certain peptides are regulated (and potentially reclassified) to balance safety with access.[3][9][1]
-
2026 updates and debates: As of 2026, there have been notable discussions about easing certain restrictions on peptides and reclassifying some previously restricted peptides for compounding use, with FDA advisory committee activity planned for mid- to late-2026. Media coverage from 2026 notes the FDA considering reclassifications for several peptides (including BPC-157) and ongoing debates about access vs safety.[4][9][3]
-
What this means for “latest FDA-approved peptides”: The landscape is evolving. The FDA has approved a handful of peptide- and oligonucleotide-based therapies in recent years, but the set of peptides currently “FDA-approved” as standalone peptide drugs is relatively small compared to other drug classes. Much of the recent activity centers on peptide-based drugs within broader modalities, regulatory discussions about safety, and plans to adjust access through advisory committee processes.[5][9][1][3]
Illustration (example of how the landscape looks):
- Approved peptide therapies (2023–2024): small number, part of a broader class (peptides/oligonucleotides).[1][5]
- Regulatory trajectory (2026): advisory committees considering reclassification to broaden compounding access, with safety considerations ongoing.[9][3]
If you’d like, I can tailor this to a specific peptide or indication (e.g., appetite regulation, metabolic signals, or anti-aging claims) and pull the most recent official FDA notices or peer-reviewed analyses to confirm current approval status and regulatory changes. I can also provide a concise timeline of key FDA actions on peptides over the past few years with direct citations.
Sources:
- 2023 FDA TIDES Harvest: nine peptide/oligonucleotide approvals.[5]
- 2024 peptide/oligonucleotide approvals and Harvest notes.[1]
- FDA consideration of easing restrictions on certain peptides and advisory meetings in 2026.[3]
- FDA discussions on peptide access via compounding and regulatory notices in 2026.[9]